Section 4.12: Clinical Pharmacology: Oncology, Immunology, and Hematology
Key Takeaways
- Chemotherapeutic agents have distinct dose-limiting toxicities, such as doxorubicin-induced cardiotoxicity and vincristine-induced peripheral neuropathy, with vincristine being fatal if administered intrathecally.
- Highly emetogenic chemotherapy regimens require a multi-drug prophylactic regimen consisting of an NK1 receptor antagonist, a 5-HT3 receptor antagonist, and dexamethasone.
- Initiation of biological DMARDs like TNF-alpha inhibitors requires mandatory pre-screening for latent tuberculosis and hepatitis B virus to prevent reactivation.
- Erythropoiesis-stimulating agents (ESAs) in chronic kidney disease are titrated to a target hemoglobin not exceeding 11 g/dL due to increased cardiovascular and thromboembolic risks.
Last updated: July 2026
Clinical Pharmacology: Oncology, Immunology, and Hematology
Oncology, immunology, and hematology cover therapeutic classes that require strict monitoring, adherence to supportive care guidelines, and understanding of patient safety precautions.
1. Oncology & Chemotherapy Regimens
Cancer chemotherapy involves cytotoxic agents with narrow therapeutic indices and high risks of severe toxicities. Pharmacists must be familiar with specific antidotes, lifetime cumulative dose limits, and preventative protocols:
Cytotoxic Class Toxicities & Clinical Pearls
| Agent / Class | Primary Toxicities | Protective Agent / Antidote | Clinical Pearls |
|---|---|---|---|
| Anthracyclines (e.g., Doxorubicin, Daunorubicin) | Cardiotoxicity (acute arrhythmias, chronic cardiomyopathy/HF). Extravasation risk (vesicant). | Dexrazoxane (cardioprotectant; used when cumulative dose exceeds thresholds; also used to treat extravasation). | Lifetime cumulative dose limit of doxorubicin is 450–550 mg/m². Red-orange discoloration of urine/sweat is normal. |
| Platinum Agents (e.g., Cisplatin, Carboplatin) | Nephrotoxicity (cisplatin), ototoxicity, severe emetogenicity. Myelosuppression (dose-limiting for carboplatin). | Amifostine (nephroprotectant). Aggressive IV hydration with normal saline is mandatory. | Carboplatin is dosed using the Calvert Formula: $\text{Dose (mg)} = \text{Target AUC} \times (\text{GFR} + 25)$. |
| Vinca Alkaloids (e.g., Vincristine, Vinblastine) | Peripheral neuropathy (dose-limiting for vincristine), severe constipation (autonomic neuropathy), extravasation (vesicant, treat with warm compresses and hyaluronidase). | None. | Vincristine is FATAL if administered intrathecally. It should only be given intravenously. Dispense in mini-bags to prevent accidental intrathecal administration. |
| Alkylating Agents (e.g., Cyclophosphamide, Ifosfamide) | Hemorrhagic cystitis (caused by the metabolite acrolein binding to bladder wall), myelosuppression. | Mesna (copiously binds acrolein in the bladder). Aggressive oral/IV hydration is required. | Mesna is mandatory for all ifosfamide doses and high-dose cyclophosphamide. |
| Bleomycin | Pulmonary toxicity (pulmonary fibrosis, pneumonitis). | None. | Lifetime cumulative dose limit is 400 units due to pulmonary toxicity risk. Baseline and periodic pulmonary function tests (DLCO) are required. |
2. Managing Oncologic Toxicities
Chemotherapy-Induced Nausea and Vomiting (CINV)
CINV prevention is based on the emetogenic potential of the chemotherapy regimen. For highly emetogenic regimens (e.g., Cisplatin, high-dose Cyclophosphamide), a 3- or 4-drug regimen is required starting on Day 1 of chemotherapy:
- NK1 Receptor Antagonist: e.g., Aprepitant (oral) or Fosaprepitant (IV). Block substance P receptors.
- 5-HT3 Receptor Antagonist: e.g., Ondansetron, Palonosetron. Block serotonin receptors in the CTZ. Side effects: headache, constipation, QT prolongation (ondansetron).
- Dexamethasone: Corticosteroid. Enhances antiemetic efficacy.
- Optional: Olanzapine (often added to form a 4-drug regimen, highly effective for delayed nausea).
Febrile Neutropenia (FN)
Febrile neutropenia is an oncologic emergency defined as:
- Fever: A single oral temperature measurement of > 38.3°C (101°F) or a sustained temperature of >= 38.0°C (100.4°F) for over one hour.
- Neutropenia: An Absolute Neutrophil Count (ANC) < 500 cells/mm³ (or an ANC expected to decrease below 500 within 48 hours).
- Management: Immediate administration of empiric IV broad-spectrum anti-pseudomonal beta-lactam antibiotics (e.g., Cefepime, Piperacillin-Tazobactam, Meropenem) is mandatory. Vancomycin is added if a catheter-related infection, pneumonia, or hemodynamic instability is present.
- Prevention: Granulocyte Colony-Stimulating Factors (G-CSF) (e.g., Filgrastim, Pegfilgrastim) are indicated as primary prophylaxis in patients receiving chemotherapy regimens with a >= 20% risk of febrile neutropenia.
3. Immunology: Rheumatoid Arthritis & SLE
Rheumatoid Arthritis (RA) DMARDs
- Methotrexate (MTX): Gold standard first-line DMARD. Inhibits dihydrofolate reductase. Dosed ONCE WEEKLY (never daily for RA). Folic acid (1–5 mg daily or 5 mg weekly) must be co-prescribed to reduce GI and hematologic toxicities. Adverse effects: hepatotoxicity, myelosuppression, interstitial pneumonitis. Contraindicated in pregnancy.
- Leflunomide: Inhibits pyrimidine synthesis. Teratogenic; requires a cholestyramine washout procedure if pregnancy is desired.
- Hydroxychloroquine: Used for mild RA or in combination. Associated with retinal toxicity (requires baseline and annual ophthalmic examinations after 5 years of use).
- Biological DMARDs (TNF-alpha inhibitors: Adalimumab, Infliximab, Etanercept): Effective but immunosuppressive. Mandatory screening for latent Tuberculosis (TB) and Hepatitis B Virus (HBV) is required before initiating any biologic DMARD due to the risk of reactivation. Live vaccines are contraindicated while receiving biologic therapy.
Systemic Lupus Erythematosus (SLE)
- Hydroxychloroquine: Fundamental therapy for all patients with SLE to reduce flares and organ damage.
- Corticosteroids: Used at the lowest effective dose for active flares.
- Immunosuppressants: Mycophenolate mofetil (preferred for lupus nephritis) or Azathioprine. Azathioprine requires checking TPMT (thiopurine methyltransferase) enzyme activity before starting to avoid severe myelosuppression.
4. Hematology: Anemias
- Iron Deficiency Anemia: Characterized by microcytic, hypochromic red blood cells ($MCV < 80$ fL) and low ferritin. Treated with oral ferrous sulfate (325 mg daily/every other day). Counsel patients to take on an empty stomach with Vitamin C (enhances absorption) and avoid antacids, dairy, and tea. Side effects: constipation, dark stools. IV iron (e.g., Iron Dextran, Ferric Carboxymaltose) is used for oral intolerance or malabsorption. Iron dextran requires a test dose due to anaphylaxis risk.
- Megaloblastic Anemias: Macrocytic ($MCV > 100$ fL). Caused by Vitamin B12 or folate deficiency. Vitamin B12 deficiency (pernicious anemia due to lack of intrinsic factor) requires IM cyanocobalamin (1000 mcg daily for a week, then weekly, then monthly) or high-dose oral therapy.
- Anemia of Chronic Kidney Disease (CKD): Caused by deficient erythropoietin production. Treated with Erythropoiesis-Stimulating Agents (ESAs): Epoetin alfa, Darbepoetin alfa. Safety Warning: target hemoglobin must not exceed 11 g/dL due to increased risks of cardiovascular events, stroke, venous thromboembolism, and tumor progression in cancer patients.
Test Your Knowledge
A patient is scheduled to receive a chemotherapy regimen containing high-dose cisplatin. Which of the following administration routes is considered an absolute contraindication for the supportive vincristine dose in the same cycle?
A
B
C
D
Test Your Knowledge
A clinical pharmacist is reviewing a chemotherapy order for a patient scheduled to receive cisplatin. Which of the following interventions is the most effective method to prevent cisplatin-induced nephrotoxicity?
A
B
C
D
Test Your Knowledge
A rheumatologist is planning to initiate adalimumab, a TNF-alpha inhibitor, for a patient with severe rheumatoid arthritis. Which of the following pre-treatment screening procedures is clinically mandatory prior to starting this biologic agent?
A
B
C
D